Outcome of the meeting of board of directors held on Friday, November 14, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natural Biocon reported its unaudited financial results for Q2 FY26 (quarter ended September 30, 2025), showing zero revenue from operations, down from Rs. 473.69 lakhs in the same quarter last year — a complete collapse in quarterly sales. The company slipped into a loss of Rs. 4.37 lakhs for Q2 FY26 versus a profit of Rs. 20.24 lakhs in Q2 FY25. For the half year ended September 2025, total income fell sharply to Rs. 166.57 lakhs from Rs. 572.34 lakhs in H1 FY25, a drop of about 71%, while profit after tax nearly halved to Rs. 9.49 lakhs from Rs. 29.99 lakhs. Basic EPS for H1 FY26 stood at Rs. 0.04 versus Rs. 0.12 in the year-ago period. The balance sheet shows a Capital Work in Progress of Rs. 328.99 lakhs and investments of Rs. 2,112.37 lakhs, with virtually no debt, indicating the company is asset-rich but operationally struggling.
Shareholders should be concerned about the near-total absence of revenue in Q2 FY26, which signals serious operational or business continuity issues; despite a clean balance sheet with no significant debt, the sharp revenue and profit erosion is a negative signal for the stock and business outlook.